Clinical trials: Glial Tumors
Brain Tumors
Establishment of a Signature of Circulating microRNA as a Tool to Aid Diagnosis of Primary Brain Tumors in Adults
MIRNA is a prospective multi-center observational study designed to explore 762 plasma microRNAs in patients with malignant CNS tumours: 60 primary glioblastoma (GBM), 20 primary CNS lymphomas and 40 brain metastases in an…
- Trial name
- MIRNA (NCT03630861)
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02839954
- Testing
- anti-MUC1 CAR-pNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Brain Tumor
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
- Trial name
- NCT05029960
- Testing
- Brivaracetam
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Rochester
Cytomegalovirus Positive, Glioblastoma
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
This phase I/II trial studies the side effects and best dose of autologous cytomegalovirus (CMV)-specific cytotoxic T cells when given together with temozolomide and to see how well they work in treating patients with…
- Conditions
- Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma
- Trial name
- NCT02661282
- Testing
- Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Stem Gliomas
Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
RATIONALE: Current therapies for a brain stem glioma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain stem gliomas.
- Trial name
- NCT00003459
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Glioblastoma
Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
This study is a prospective Bayesian adaptive randomized phase II clinical trial of enhanced adjuvant therapy for newly diagnosed glioblastoma with partial surgical resection or short-term progression.
- Trial name
- NCT06936046
- Testing
- Dual antibody A, Dual antibody B, Modified Stupp
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Glioblastoma
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma
Part 1 (dose escalation, safety, and preliminary efficacy) Part 1 is a non-randomised, single-arm design in 12 participants with recurrent GBM suitable for maximal safe surgical resection.
- Trial name
- OPTICAL (NCT07356973)
- Testing
- irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM
- Where
- United Kingdom
- Volunteers
- 147 people
- Sponsor
- CRISM Therapeutics LTD
Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00499473
- Testing
- sunitinib malate, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. External-beam radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00053183
- Testing
- conventional surgery, brachytherapy, radiation therapy
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioma (Diagnosis)
GliomaAI-MG: MRI-Based Detection of Molecular Glioblastoma
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-MG can help detect a specific molecular type of brain tumour called molecular glioblastoma using routine MRI scans.
- Conditions
- Glioma, Glioma (Diagnosis), Glioblastom WHO Grade 4
- Trial name
- GliomaAI-MG (NCT07664254)
- Testing
- GliomaAI-MG
- Where
- India
- Volunteers
- 1,372 people
- Sponsor
- Deep Learning Institute of Radiological Sciences
Relapsed Cancer, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol).
- Trial name
- GBrecurr (NCT06430424)
- Testing
- Relapsed glioblastoma
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Bordeaux
Brain (Nervous System) Cancers, Glioma
Connectome-guided Onco-functional Resection With Tractography-Extended Neuronavigation in Brain Tumor Surgery
Brain tumor surgery in so-called "eloquent" brain areas aims to remove as much tumor as possible while preserving neurological functions.
- Conditions
- Brain (Nervous System) Cancers, Glioma, Brain Metastasases, Brain Connectivity
- Trial name
- CORTEx (NCT07717827)
- Testing
- Connectome-guided network-based neuronavigation, Advanced diffusion MRI tractography and connectome pipeline
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- ARNAS Civico Di Cristina Benfratelli Hospital
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00498927
- Testing
- temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Grade II/III Glioma
CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas
The management of lower-grade gliomas (Diffuse low-grade and intermediate-grade gliomas, WHO II and III) is largely based on surgery followed by radiotherapy.
- Trial name
- NCT02766270
- Testing
- Temozolomide, Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Brain Tumors, Spinal Cord Tumors
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
- Trial name
- NCT00826241
- Testing
- Temozolomide, Lapatinib
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Recurrent or Progressive High-grade Glioma
Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma
This is a phase 1 open label study to establish the safety, tolerability, maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), and preliminary efficacy of a single dose of JCXH-211.
- Trial name
- SERIL (NCT06468605)
- Testing
- JCXH-211
- Sponsor
- Duke University
Glioblastoma, Anaplastic Astrocytoma
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
- Trial name
- NCT03603405
- Testing
- ADV/HSV-tk (gene therapy)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- The Methodist Hospital Research Institute
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
This pilot phase II trial is studying the side effects and best dose of erlotinib when given with temozolomide and radiation therapy and to see how well they work in treating patients with glioblastoma multiforme or other brain…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00039494
- Testing
- erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide
- Where
- 139 sites in United States
- Volunteers
- 171 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Oligodendroglioma
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
- Trial name
- NCT05484622
- Testing
- Vorasidenib, Pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Institut de Recherches Internationales Servier
Malignant Glioma
Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma
The purpose of this study is to determine the toxicity and tolerance of Myocet® in children and adolescents with refractory or relapsed malignant glioma, with a dose diminished of 20% of the dose recommended for adults and a dose…
- Trial name
- MYOCET (NCT02861222)
- Testing
- Doxorubicin
- Where
- 7 sites in France
- Volunteers
- 13 people
- Sponsor
- Central Hospital, Nancy, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.